Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Front Public Health ; 11: 1115055, 2023.
Article in English | MEDLINE | ID: mdl-36969669

ABSTRACT

Background: Invasive fungal infections have presented a challenge in treatment. In the past, it was known that the frontrunner in such infections is Candida albicans with little emphasis placed on non-albicans Candida species (NAC). Studies worldwide have shown a rise in fungal infections attributed to non-albicans Candida species. The aim of this study is to describe the epidemiology of NAC infections along with an overview of resistance in Lebanese hospitals. Methods: This is a two-year observational multi-central descriptive study. Between September 2016 and May of 2018, a total of 1000 isolates were collected from 10 different hospitals distributed all over the country. For the culture, Sabouraud Dextrose Agar was used. Antifungal Susceptibility was evaluated by determining the Minimum Inhibitory Concentration (MIC) in broth (microdilution) of the different antifungal treatments. Results: Out of the 1000 collected isolates, Candida glabrata, being the most isolated species (40.8%), followed by Candida tropicalis: 231(23.1%), Candida parapsilosis: 103(10.3%), and other NAC species at lower percentage. Most of these isolates (88.67%) were susceptible to posaconazole, 98.22% were susceptible to micafungin, and 10% were susceptible to caspofungin. Conclusion: The change of etiology of fungal infections involving a significant increase in NAC cases is alarming due to the different antifungal susceptibility patterns and the lack of local guidelines to guide the treatment. In this context, proper identification of such organisms is of utmost importance. The data presented here can help in establishing guidelines for the treatment of candida infections to decrease morbidity and mortality. Future surveillance data are needed.


Subject(s)
Antifungal Agents , Mycoses , Humans , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Candida , Microbial Sensitivity Tests , Hospitals , Mycoses/drug therapy
2.
BMC Nephrol ; 18(1): 191, 2017 Jun 07.
Article in English | MEDLINE | ID: mdl-28592319

ABSTRACT

BACKGROUND: Vascular calcifications are highly prevalent in hemodialysis patients. Dephosphorylated-uncarboxylated MGP (dp-ucMGP) was found to increase in vitamin K-deficient patients and may be associated with vascular calcifications. Supplementation of hemodialysis patients with vitamin K2 (menaquinone-7) has been studied in Europe with a maximum 61% drop of dp-ucMGP levels. The aim of this study is to assess first the drop of dp-ucMGP in an Eastern Mediterranean cohort after vitamin K2 treatment and second the correlation between baseline dp-ucMGP and vascular calcification score. METHODS: This is a prospective, pre-post intervention clinical trial involving 50 hemodialysis patients who received daily 360 µg of menaquinone-7 for 4 weeks. At baseline they were assessed for plasma dp-ucMGP levels and vascular calcification scores (AC-24) as well as for other demographic, clinical and biological variables. Dp-ucMGP levels were measured a second time at 4 weeks. RESULTS: At baseline, dp-ucMGP levels were extremely elevated with a median of 3179.15 (1825.25; 4339.50) pM and correlated significantly with AC-24 (Spearman's rho = 0.43, P = 0.002). Using a bivariate regression analysis, the association between dp-ucMGP levels and AC-24 was most significant when comparing dp-ucMGP levels less than 1000 to those more than 1000 pM (P = 0.02). Dp-ucMGP levels higher than 5000 pM were significantly associated with females, patients with recent fracture and patients with lower serum albumin (respectively P = 0.02, 0.004 and 0.046). The average drop of dp-ucMGP at 4 weeks of treatment was found to be 86% with diabetics having the lowest drop rate (P = 0.01). CONCLUSION: Vitamin K deficiency, as assessed by high dp-ucMGP levels, is profound in hemodialysis patients from the Eastern Mediterranean region and it is significantly correlated with vascular calcifications. Daily 360 µg of menaquinone-7, given for 4 weeks, effectively reduces dp-ucMGP in this population. Future studies are needed to assess the changes in vascular calcifications in hemodialysis patients treated with vitamin K2 over a longer follow-up period. TRIAL REGISTRATION: The clinical trial was registered on clinicaltrials.gov (Identification number NCT02876354 , on August 11, 2016).


Subject(s)
Calcium-Binding Proteins/blood , Extracellular Matrix Proteins/blood , Renal Dialysis/adverse effects , Vitamin K 2/therapeutic use , Vitamin K Deficiency/blood , Vitamin K Deficiency/drug therapy , Aged , Aged, 80 and over , Biomarkers/blood , Female , Humans , Male , Middle Aged , Phosphorylation/physiology , Prospective Studies , Renal Dialysis/trends , Risk Factors , Treatment Outcome , Vitamin K Deficiency/etiology , Matrix Gla Protein
3.
Article in English | MEDLINE | ID: mdl-23811496

ABSTRACT

Waldenstrom's macroglobulinemia (WM) is considered by the Revised European American Lymphoma (REAL) and World Health Organization (WHO) as a clinical lympho plasmacytic syndrome associated with high monoclonal (IgM) secretion. The hyper viscosity syndrome is associated with several clinical disorders of monoclonal IgM. Patients with clinical symptoms of hyper viscosity should be treated with plasma pheresis, which is limited by its non-selective removal of all plasma components. These limitations have steered efforts to find a more specific removal according to clinical needs and avoiding plasma components replacement. Removal by specific adsorption is the most powerful selective apheresis technique. The active adsorbed ligand is covalently bound to an insoluble matrix through which plasma is passed. Amino acids have been introduced as ligands in clinical apheresis for the removal of auto antibodies associated with autoimmune diseases. The present preliminary study describes the binding of monoclonal IgM antibodies from sera of patients with WM, on histidine immobilized to activated sepharose. The advantages of efficient binding and elution, suggest histidine adsorbents as prospective clinical means suitable for the removal of monoclonal IgM from sera of patients diagnosed with WM. The advantages of efficient adsorption and elution, non toxicity of histidine, good selectivity, good stability, as well as their low cost strongly suggest histidine adsorbents as prospective clinical means suitable for the removal of monoclonal IgM from sera of patients diagnosed with WM.


Subject(s)
Histidine/chemistry , Immunoglobulin M/blood , Immunoglobulin M/isolation & purification , Plasmapheresis/methods , Waldenstrom Macroglobulinemia/blood , Waldenstrom Macroglobulinemia/therapy , Adsorption , Aged , Female , Humans , Male , Middle Aged , Waldenstrom Macroglobulinemia/diagnosis
4.
Prep Biochem Biotechnol ; 38(2): 139-51, 2008.
Article in English | MEDLINE | ID: mdl-18320465

ABSTRACT

A method based on histidine ligand affinity chromatography has been utilized for the separation of DNA hydrolyzing autoantibodies from sera of patients suffering from systemic lupus erythematosus and primary antiphospholipid syndrome using the gel, histidyl-aminohexyl-sepharose. The separation of autoantibodies was carried out under mild chromatographic conditions. Human IgG subclass distribution in the different fractions separated on the column was studied by enzyme-linked immunosorbent assay. The purified DNA hydrolyzing autoantibodies were shown to hydrolyze plasmid DNA.


Subject(s)
Antibodies, Antinuclear/blood , Antiphospholipid Syndrome/blood , Autoantibodies/blood , Chromatography, Affinity/methods , Histidine/immunology , Immunoglobulin G/immunology , Lupus Erythematosus, Systemic/blood , Adult , Blood Chemical Analysis/methods , Female , Humans , Male
5.
J Clin Microbiol ; 43(7): 3309-13, 2005 Jul.
Article in English | MEDLINE | ID: mdl-16000453

ABSTRACT

A prospective study was carried out to assess the extent of carriage of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae at both hospital and community levels in Lebanon. A total of 1,442 fecal samples were collected from hospital-based patients and 58 from health care workers of six Lebanese tertiary care general hospitals located in different areas of Lebanon between January and March 2003. A total of 382 fecal samples were also collected from healthy subjects between April and June 2003. The samples analysis led to the identification of 118 strains as ESBL producers based on the synergistic effects between clavulanate and selected beta-lactams (ceftazidime and cefotaxime). These strains were isolated from 72 subjects: 61 patients, 2 health care workers, and 9 healthy subjects. One representative strain per subject was selected, and a total of 72 nonduplicate ESBL producers, including a high majority of Escherichia coli (n = 56), Klebsiella pneumoniae (n = 9), Enterobacter cloacae (n = 6), and Citrobacter freundii (n = 1), were characterized. The molecular analysis revealed that the majority of the strains (83%) express CTX-M-15 ESBL (pI 8.6). SHV-5a ESBL (pI 8.2) was produced by 18% of the strains. DNA macrorestriction analysis of ESBL-producing E. coli presented 38 different genotypes, revealing the absence of clonal link among these strains. In addition to the fact that the present study highlights the emergence and the countrywide dissemination of CTX-M-15-producing E. coli in Lebanon, it represents the first report of an SHV-5a-producing C. freundii.


Subject(s)
Community-Acquired Infections/epidemiology , Cross Infection/epidemiology , Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae/enzymology , beta-Lactamases/metabolism , Anti-Bacterial Agents/pharmacology , Community-Acquired Infections/microbiology , Community-Acquired Infections/transmission , Cross Infection/microbiology , Cross Infection/transmission , Drug Resistance, Bacterial , Enterobacteriaceae/drug effects , Enterobacteriaceae/isolation & purification , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae Infections/transmission , Humans , Lebanon/epidemiology , Microbial Sensitivity Tests , Polymerase Chain Reaction , beta-Lactam Resistance , beta-Lactamases/genetics , beta-Lactams/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...